These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17910277)

  • 21. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
    Kirby BD; Al Ahmar R; Withers TR; Valentine ME; Valentovic M; Long TE; Gaskins JR; Yu HD
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
    [No Abstract]   [Full Text] [Related]  

  • 22. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS
    Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
    Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
    Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of iron depletion on antimicrobial activities against planktonic and biofilm Pseudomonas aeruginosa.
    Cai Y; Yu XH; Wang R; An MM; Liang BB
    J Pharm Pharmacol; 2009 Sep; 61(9):1257-62. PubMed ID: 19703377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Moskowitz SM; Foster JM; Emerson J; Burns JL
    J Clin Microbiol; 2004 May; 42(5):1915-22. PubMed ID: 15131149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic and phenotypic comparison of environmental and patient-derived isolates of
    Ramsay KA; Wardell SJT; Patrick WM; Brockway B; Reid DW; Winstanley C; Bell SC; Lamont IL
    J Med Microbiol; 2019 Nov; 68(11):1591-1595. PubMed ID: 31553303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
    Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis.
    Dales L; Ferris W; Vandemheen K; Aaron SD
    Eur J Clin Microbiol Infect Dis; 2009 Oct; 28(10):1275-9. PubMed ID: 19575248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients.
    Fricks-Lima J; Hendrickson CM; Allgaier M; Zhuo H; Wiener-Kronish JP; Lynch SV; Yang K
    Int J Antimicrob Agents; 2011 Apr; 37(4):309-15. PubMed ID: 21382698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells.
    Anderson GG; Moreau-Marquis S; Stanton BA; O'Toole GA
    Infect Immun; 2008 Apr; 76(4):1423-33. PubMed ID: 18212077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
    Maiden MM; Zachos MP; Waters CM
    J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa.
    Soren O; Rineh A; Silva DG; Cai Y; Howlin RP; Allan RN; Feelisch M; Davies JC; Connett GJ; Faust SN; Kelso MJ; Webb JS
    J Antimicrob Chemother; 2020 Jan; 75(1):117-125. PubMed ID: 31682251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activities of tobramycin and polymyxin E against Pseudomonas aeruginosa biofilm-coated medical grade endotracheal tubes.
    Tarquinio K; Confreda K; Shurko J; LaPlante K
    Antimicrob Agents Chemother; 2014; 58(3):1723-9. PubMed ID: 24379207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Organic Acids and Their Salts Potentiate the Activity of Selected Antibiotics against Pseudomonas aeruginosa Biofilms Grown in a Synthetic Cystic Fibrosis Sputum Medium.
    Bao X; Bové M; Coenye T
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0187521. PubMed ID: 34807756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.